Diseases, Conditions, Syndromes

No benefit seen with rituximab for chronic fatigue syndrome

(HealthDay)—In patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), B-cell depletion using several infusions of rituximab over 12 months is not associated with clinical improvement, according to a ...

HIV & AIDS

One-month regimen noninferior for preventing HIV-related TB

(HealthDay)—For HIV-infected patients, a one-month regimen of rifapentine and isoniazid is noninferior to nine months of isoniazid alone for preventing tuberculosis, according to a study published in the March 14 issue ...

Medical research

Harmful placebos

How could a sugar pill placebo cause harm? A new review of data from 250,726 trial participants has found that 1 in 20 people who took placebos in trials dropped out because of serious adverse events (side effects). Almost ...

Diseases, Conditions, Syndromes

Mild adverse events common with chiropractic care

(HealthDay)—Adverse events are common after chiropractic care, but seem to be due to non-specific effects and are mostly benign, according to a study published in the Sept. 15 issue of Spine.

Cardiology

ESC: Colchicine effective for acute pericarditis

(HealthDay)—Colchicine is more effective than placebo in reducing the risk of incessant or recurrent pericarditis in patients with acute pericarditis, according to a study published online Sept. 1 in the New England Journal ...

Arthritis & Rheumatism

Tofacitinib ups rheumatoid arthritis treatment response

(HealthDay)—The addition of tofacitinib to rheumatoid arthritis (RA) treatment regimens improves patient response to non-biologic disease-modifying antirheumatic drugs (DMARDs), according to a study published in the Aug. ...

page 1 from 4